ReviewTargeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients
Keywords
Cited by (0)
Rasha Abu-Eid: Dr Abu-Eid completed her PhD in Oral Pathology in 2005 from the University of Birmingham, England. After holding different positions in the University of Birmingham, University of Jordan and the University of Aberdeen, in 2011, she was successful in securing a research fellowship from the King Hussein Institute for Biotechnology and Cancer to conduct research in the field of cancer immunology in USA. In October 2016, she re-joined the University of Aberdeen as a Senior Lecturer in Oral Sciences and is currently the lead for cancer research at the Institute of Dentistry.
Frank James Ward: Frank Ward studied Immunology at King's College London and received his PhD from the University of London in 1996. He moved to the University of Aberdeen in 2000 to pursue his main research interest, which is to investigate how the immune system maintains immunological tolerance, particularly in autoimmune disease and cancer. During the last 10 years he has worked on the less well-studied soluble isoform of CTLA-4 as a potential checkpoint inhibitor target for a range of cancers. Frank has published data in several journals based on patient focused studies around sCTLA-4 and has presented at national and international conferences.